Essential Thrombocythemia
Essential thrombocythemia (ET) — also spelled essential thrombocythaemia — is a chronic bone marrow disorder that causes the body to produce too many platelets. It is usually first detected on a routine blood test showing a persistently high platelet count. While ET can increase the risk of blood clots, most people have few symptoms and can live a normal life expectancy with appropriate monitoring and treatment.
Unlike reactive thrombocytosis — where platelet count rises temporarily in response to infection, inflammation, or iron deficiency — ET is a clonal disorder driven by an acquired genetic mutation in bone marrow stem cells. The primary treatment goal is reducing the risk of blood clot complications rather than eliminating the disease.
Why this matters for your blood test results
- ET is most often first suspected from a routine CBC showing a persistently elevated platelet count — typically above 450 × 10³/µL, and often 600, 800, or even over 1,000 × 10³/µL in untreated cases
- Plateletcrit (PCT) is frequently elevated in ET due to the combination of high platelet count and often increased mean platelet volume (MPV)
- JAK2 V617F mutation is present in approximately 50–60% of ET cases; CALR mutations account for approximately 25%; MPL mutations approximately 5%
- Around 10% of ET cases are triple-negative (no JAK2, CALR, or MPL mutation detected)
- LDH may be mildly elevated in some cases reflecting increased cell turnover
- Tracking platelet count trends over time in HealthMatters is particularly valuable in ET — the trajectory matters as much as any single result
Is essential thrombocythemia dangerous?
For most people, ET is not immediately dangerous. The main risks come from blood clots — which can cause stroke, deep vein thrombosis, or pulmonary embolism — and from bleeding when the platelet count is very high (typically above 1,500 × 10³/µL) due to acquired von Willebrand factor deficiency. Risk varies considerably between individuals based on age, mutation type, and cardiovascular risk factors. Many patients remain stable for decades with appropriate management and never experience a serious complication.
Life expectancy and prognosis
Most people with ET have a near-normal life expectancy. Median survival often exceeds 20–30 years from diagnosis, and many patients are diagnosed in middle age or later and live normal lifespans with well-controlled disease.
Long-term prognosis depends on several factors:
- Age — older patients have higher thrombotic risk
- Mutation type — JAK2-positive ET carries a slightly higher thrombotic risk; CALR-mutated ET has a higher risk of progression to myelofibrosis over time
- History of thrombosis — prior clot events significantly increase future risk
The main long-term risks are thrombosis (the most common complication), progression to myelofibrosis (in approximately 5–10% of patients over 10–15 years), and transformation to acute leukemia (in less than 5% of cases). ET does not typically transform into polycythemia vera — PV and ET are parallel myeloproliferative neoplasms rather than sequential stages.
How essential thrombocythemia is detected
ET is most often discovered incidentally on a routine CBC when a persistently elevated platelet count is identified. The finding prompts further investigation:
- Repeat CBC to confirm the elevation is persistent rather than reactive
- Mutation testing for JAK2 V617F, CALR, and MPL
- Bone marrow biopsy in most cases to confirm megakaryocytic proliferation and exclude other myeloid disorders
- Exclusion of reactive causes — iron deficiency, infection, inflammation, splenectomy
A single elevated platelet count is not enough to diagnose ET. The WHO criteria require persistence, mutation confirmation or exclusion of other disorders, and characteristic bone marrow findings.
Types of essential thrombocythemia
ET is classified primarily by driver mutation, which influences prognosis and some treatment decisions:
JAK2 V617F-positive ET — the most common subtype, associated with a slightly higher thrombotic risk and a small increased risk of transformation to myelofibrosis over time.
CALR-mutated ET — generally lower thrombotic risk than JAK2-positive ET but higher risk of progression to myelofibrosis long-term. Type 1 and Type 2 CALR mutations carry different prognostic implications.
MPL-mutated ET — less common; clinically similar to JAK2-positive ET.
Triple-negative ET — no driver mutation identified; typically lower thrombotic risk; requires careful exclusion of reactive causes and other myeloid disorders.
Symptoms
Many people with ET have no symptoms at diagnosis and are identified incidentally when a routine blood count reveals an elevated platelet count. When symptoms occur they are most often related to abnormal platelet clotting or impaired platelet function:
- Headaches, dizziness, and visual disturbances
- Burning, redness, and pain in the hands or feet (erythromelalgia) — a characteristic symptom caused by small vessel clotting
- Tingling or numbness in the extremities
- Fatigue
- Enlarged spleen (splenomegaly) — present in a minority of patients
- Blood clot events — deep vein thrombosis, pulmonary embolism, stroke, or transient ischemic attack — may be the presenting feature in some patients
- Paradoxical bleeding — easy bruising, nosebleeds, or gastrointestinal bleeding, particularly when the platelet count is very high (above 1,500 × 10³/µL)
Causes and diagnosis
ET is caused by an acquired somatic mutation in a hematopoietic stem cell that activates the JAK-STAT signaling pathway, driving uncontrolled megakaryocyte proliferation and platelet overproduction. The mutation is not inherited and is not passed to children.
Diagnosis requires meeting the 2016 WHO criteria, which include a platelet count ≥450 × 10³/µL on at least two occasions, bone marrow biopsy findings showing megakaryocytic proliferation without significant reticulin fibrosis, presence of a JAK2, CALR, or MPL mutation (or exclusion of other myeloid disorders in triple-negative cases), and exclusion of reactive thrombocytosis.
Risk stratification using the IPSET-thrombosis score — incorporating age, JAK2 mutation status, cardiovascular risk factors, and prior thrombotic events — guides treatment decisions.
Treatment
Treatment in ET aims to reduce the risk of thrombotic and bleeding complications. Not all patients require immediate treatment — many low-risk individuals are monitored without cytoreductive therapy.
Low-risk ET (age under 60, no prior thrombosis, low cardiovascular risk) Observation with regular blood count monitoring is appropriate. Low-dose aspirin is often recommended for JAK2-positive patients to reduce thrombotic risk.
High-risk ET (age 60 or older, prior thrombotic event, or JAK2-positive with cardiovascular risk factors) Cytoreductive therapy is recommended to lower the platelet count and reduce clot risk:
- Hydroxyurea — standard first-line agent; effective for long-term platelet count control
- Anagrelide — platelet-specific alternative or second-line option
- Interferon-alpha (pegylated) — increasingly preferred in younger patients and during pregnancy; can induce molecular remission in some cases
- Low-dose aspirin — used alongside cytoreductive therapy in most high-risk patients
Treatment typically aims to maintain platelet count below 400–450 × 10³/µL, though targets are individualised. Pregnancy in ET requires specialist management — hydroxyurea is avoided due to teratogenicity, with interferon-alpha or low-molecular-weight heparin preferred depending on the clinical situation.
FAQ
Is essential thrombocythemia cancer? ET is classified as a myeloproliferative neoplasm — a chronic clonal bone marrow disorder. It is often described as a form of blood cancer, though it behaves very differently from acute leukemia. Most people with well-managed ET have a near-normal life expectancy compatible with a good quality of life.
What is the life expectancy with essential thrombocythemia? Most people with ET have a near-normal life expectancy. Median survival often exceeds 20–30 years from diagnosis. Prognosis depends on age, mutation type, and whether complications such as thrombosis have occurred. The main risks are blood clots and, in a minority of patients, progression to myelofibrosis or leukemia over time.
Can essential thrombocythemia transform into leukemia? A small percentage of ET cases transform over time — most commonly to myelofibrosis (approximately 5–10% over 10–15 years) and rarely to acute leukemia (less than 5%). ET does not typically transform into polycythemia vera. Regular monitoring is important to detect any changes early.
Related biomarkers
Key laboratory markers in ET include platelet count (persistently elevated, typically above 450 × 10³/µL), plateletcrit (PCT — elevated reflecting high platelet mass), mean platelet volume (MPV), JAK2 V617F mutation, CALR mutation, MPL mutation, LDH, and complete blood count with differential. Tracking platelet count and PCT trends over time in HealthMatters helps document disease trajectory and treatment response.
Bottom line
Essential thrombocythemia is a chronic bone marrow disorder causing persistent platelet overproduction, usually first identified through a high platelet count on a routine CBC. While it carries risks of blood clots and rarely disease progression, most people with ET have a near-normal life expectancy with appropriate management. Treatment is risk-stratified — many low-risk patients are monitored without medication, while high-risk patients benefit from cytoreductive therapy and aspirin to reduce thrombotic complications.
Show more